AZN · Astrazeneca plc
United States · RS rating 36 · As of 2026-10-14
| Price | 162.03 USD |
|---|---|
| 1-day change | +4.0% |
| RS rating (overall / 1M / 3M / 12M) | 36 / 70 / 46 / 39 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 27 / 44 |
| Industry group (rank) | Medical-Diversified (32) |
| EPS growth Q/Q | +32.2% |
| Sales growth Q/Q | +2.0% |
| Distance from 52-week high | +22.6% |
| Market cap (USD) | $298.1B |